Philips to partner with China to take healthcare solutions global

Dutch health technology company Philips plans to deepen its research and development activities in China and bring more locally developed healthcare solutions to global markets, leveraging the country's research capabilities and innovation ecosystem, a senior executive said.

"China is not only Philips' second-largest market, but also an important engine of global innovation," said Liu Ling, executive committee member and executive vice-president of Philips and chief regional leader of Philips Greater China.

Since establishing its first joint venture in China in 1985, Philips has expanded its local workforce to nearly 7,000 employees, including about 1,000 R&D staff. It has established a "1+4" network of R&D and innovation centers and five manufacturing bases. In September, it opened its China R&D and Innovation Headquarters.

The development reflects a shift in Philips' strategy in China, moving from "growing in China" to "co-creating with China and building global competitiveness from China", Liu said.

China's clinical needs and medical resources provide opportunities for Philips to collaborate with hospitals, companies, and research institutions on healthcare solutions.

Bert van Meurs, executive vice-president and global business leader of image-guided therapy, co-responsible for diagnosis and treatment, and a member of the Philips Executive Committee, said demand for minimally invasive procedures was expected to rise as populations age and chronic diseases become more prevalent. He added that market competition could encourage technological advancements and new solutions for patients.

Artificial intelligence is another focus. Van Meurs said its clinical application required not only advanced algorithms, but also reliable data access, governance, and trust, alongside training for healthcare professionals.